9 results
Phase I:-To determine the maximum tolerated dose (MTD) and recommended phase II dose level (RDL) of Bortezomib administered once weekly, and of Lenalidomide administered for 3 weeks when combined with Dexamethasone in a 28-days schedule.Phase II:-To…
1. Standardized reporting of occurrence of metabolic adverse events after treatment with glucocorticoid pulse therapy in chronic rheumatoid arthritis patients (who have exacerbation of disease).2. Determing if metabolic adverse events due to…
PrimaryTo assess the extended overall response rates of orally administered TKI258, at 500 mg/day, on a five days on and two days off dosing schedule, in groups of patients with relapsed or refractory multiple myeloma who are* with t(4;14)…
To determine the antileukemic activity of combination chemotherapy including bortezomib as reinduction therapy in childhood relapsed/refractory ALL.
The objective of this study is to test the hypothesis that in patients with inflammatory neuropathies and conduction blocks, corticosteroid treatment leads to:1. Hyperpolarization and reduced excitability of motor axons. 2. An increase of the number…
(1) Determination of the effect of dexamethasone on the biodistribution and kinetics of [11C]TMZ in GBM patients. (2) The effect of DXM on CBF. If there is an effect of DXM on CBF: (3) The effect of blood flow in the brain on [11C]TMZ uptake.
To establish the safety profile of daratumumab when given in combination with bortezomib and dexamethasone in subjects with relapsed or refractory MM
To compare progression-free survival in subjects with relapsed multiple myeloma who are receiving CRd vs PFS in subjects receiving Rd alone.
Evaluation of the effect of salvage therapy with R-DHAP followed by reduced-intensity conditioning and allogeneic stem cell transplantation from a sibling or unrelated donor